JP5300772B2 - 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料 - Google Patents
新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料 Download PDFInfo
- Publication number
- JP5300772B2 JP5300772B2 JP2010073674A JP2010073674A JP5300772B2 JP 5300772 B2 JP5300772 B2 JP 5300772B2 JP 2010073674 A JP2010073674 A JP 2010073674A JP 2010073674 A JP2010073674 A JP 2010073674A JP 5300772 B2 JP5300772 B2 JP 5300772B2
- Authority
- JP
- Japan
- Prior art keywords
- strain
- helicobacter pylori
- lactobacillus gasseri
- lactic acid
- acid bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000013305 food Nutrition 0.000 title claims description 64
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title description 130
- 241000894006 Bacteria Species 0.000 title description 69
- 235000014655 lactic acid Nutrition 0.000 title description 65
- 239000004310 lactic acid Substances 0.000 title description 65
- 239000003814 drug Substances 0.000 title description 23
- 241000590002 Helicobacter pylori Species 0.000 claims description 110
- 229940037467 helicobacter pylori Drugs 0.000 claims description 109
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 100
- 230000000844 anti-bacterial effect Effects 0.000 claims description 25
- 208000007882 Gastritis Diseases 0.000 claims description 21
- 239000003242 anti bacterial agent Substances 0.000 claims description 16
- 239000003018 immunosuppressive agent Substances 0.000 claims description 14
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 12
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 12
- 239000003699 antiulcer agent Substances 0.000 claims description 12
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 11
- 210000000447 Th1 cell Anatomy 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 208000000718 duodenal ulcer Diseases 0.000 claims description 4
- 201000005917 gastric ulcer Diseases 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 description 37
- 239000000047 product Substances 0.000 description 35
- 238000012360 testing method Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 239000000427 antigen Substances 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 230000001506 immunosuppresive effect Effects 0.000 description 17
- 230000004083 survival effect Effects 0.000 description 17
- 208000008469 Peptic Ulcer Diseases 0.000 description 16
- 108010074328 Interferon-gamma Proteins 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 14
- 102100037850 Interferon gamma Human genes 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 208000025865 Ulcer Diseases 0.000 description 12
- 231100000397 ulcer Toxicity 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 230000000767 anti-ulcer Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 206010062016 Immunosuppression Diseases 0.000 description 9
- 230000009422 growth inhibiting effect Effects 0.000 description 9
- 208000011906 peptic ulcer disease Diseases 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 238000012258 culturing Methods 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- 210000004051 gastric juice Anatomy 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000008105 immune reaction Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000001986 peyer's patch Anatomy 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 108020004465 16S ribosomal RNA Proteins 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007621 bhi medium Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 239000006872 mrs medium Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010008132 Cerebral thrombosis Diseases 0.000 description 3
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010017866 Gastritis haemorrhagic Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000589989 Helicobacter Species 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 235000012015 potatoes Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- -1 Patches Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011587 gastric lymphoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002957 persistent organic pollutant Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Landscapes
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
ヒト糞便1gにリン酸緩衝生理食塩水(PBS)9mlを加えて混合し、さらにPBSで段階的に希釈した。希釈液をラクトバチルス選択培地(0.8%Lab−lemco powder(Oxoid製)及び1.5%酢酸ナトリウムを含むLBS寒天培地(BBL製))に塗抹し、嫌気条件下、37℃で2〜3日間の培養を行った。形成されたコロニーを釣菌し、MRS寒天培地(Difco製)に画線接種し同様に培養した。さらに同じ操作を行い、単一のコロニーを形成する乳酸菌を分離した。得られた分離株について、菌学的性質及び16SrRNA遺伝子の塩基配列を決定した。
本試験では、ラクトバチルス・ガセリMCC1183株の低pH環境における生残性を確認することを目的とした。
ラクトバチルス・ガセリMCC1183株、ラクトバチルス・ガセリOLL 2716株(FERM BP−6999)、及びラクトバチルス・ラムノサスGG株(ATCC 53103)を含む110株の乳酸菌を試験試料とした。ラクトバチルス・ガセリOLL
2716株(FERM BP−6999)は高い胃酸耐性を有すると報告されている菌株である。また、塩化ナトリウム(国産化学製)の0.2%水溶液、及びペプシン(Sigma製)の0.35%水溶液を調製したのち、pH1.4〜2.0の範囲となるように混合し、これを人工胃液とした。
各乳酸菌を、MRS培地(Difco製)で培養(37℃、16時間)し、乳酸菌培養液を得た。得られた乳酸菌培養液を人工胃液に0.01%で添加し、37℃で2時間インキュベーションした。インキュベーション前後での生菌数をMRS寒天培地(Difco製)を用いて測定し、生残性を算出した。
ラクトバチルス・ガセリMCC1183株を試験群、ラクトバチルス・ガセリOLL 2716株(FERM BP−6999)を比較群として、人工胃液耐性試験の結果を図1に示す。
本試験では、ラクトバチルス・ガセリMCC1183株のヘリコバクター・ピロリ増殖抑制効果を確認することを目的とした。
乳酸菌として、ラクトバチルス・ガセリMCC1183株、ラクトバチルス・ガセリOLL 2716株(FERM BP−6999)、及びラクトバチルス・ラムノサスGG株(ATCC 53103)を用いた。ラクトバチルス・ガセリOLL 2716株(FERM BP−6999)、及びラクトバチルス・ラムノサスGG株(ATCC 53103)は、いずれもヘリコバクター・ピロリ増殖抑制効果が知られている株である。また、ヘリコバクター・ピロリとして、ヘリコバクター・ピロリ(ATCC 43504T)を用いた。
MRS培地(Difco製)で培養(37℃、16時間)した乳酸菌の培養液を、5%非働化ウシ胎仔血清(FCS)を含有するBHI培地(Difco製)で希釈し、乳酸菌濃度が1×109cfu/mlになるように650nmにおける吸光度に基づいて調製し、乳酸菌懸濁液とした。ヘリコバクター・ピロリを5%FCS含有BHI培地に接種し、10%CO2存在下で37℃、24時間培養し、ヘリコバクター・ピロリ濃度が1×107cfu/mlになるように調製し、ヘリコバクター・ピロリ懸濁液とした。4mlの5%FCS含有BHI培地に、0.5mlのヘリコバクター・ピロリ懸濁液と0.5mlの乳酸菌懸濁液とを添加し、10%CO2存在下で37℃、12時間培養した。
結果を図2に示す。培養前のヘリコバクター・ピロリ菌数は0.946×106cfu/mlであった。対照群では、培養後に5.95×106cfu/mlとなり、培養前と比較して6倍以上の濃度に増殖した。また、ヘリコバクター・ピロリ増殖抑制効果を有することが知られている既知の乳酸菌と混合した比較群1及び2では、培養後のヘリコバクター・ピロリ菌数はそれぞれ1.87×106cfu/ml、2.05×106cfu/mlであり、培養前と比較していずれも2倍以上の濃度に増殖した。
本試験は、ラクトバチルス・ガセリMCC1183株のヘリコバクター・ピロリの抗原特異的Th1反応に対する抑制効果を確認することを目的とした。具体的には、マウスパイエル板由来の抗原提示細胞とヘリコバクター・ピロリ抗原で感作したマウスのT細胞にヘリコバクター・ピロリ加熱菌体を添加することで誘導されるIFN−γの産生量を指標とした。
乳酸菌として、ラクトバチルス・ガセリMCC1183株及びラクトバチルス・ガセリOLL 2716株(FERM BP−6999)を用いた。ヘリコバクター・ピロリとして、ヘリコバクター・ピロリ(ATCC 43504T)を用いた。
各乳酸菌をMRS培地で16時間培養し、菌体をPBSで2回洗浄し、さらに蒸留水で2回洗浄した後に蒸留水で懸濁し、凍結乾燥を行った。凍結乾燥した菌体をPBSで懸濁して10mg/mlに調整し、100℃、30分間の加熱処理を行い、乳酸菌加熱菌体とした。ヘリコバクター・ピロリを5%FCS含有BHI培地で24時間培養し、菌体をPBSで2回洗浄し、PBSで10mg/mlに調整した。さらに、100℃、30分間の加熱処理を行い、ヘリコバクター・ピロリ加熱菌体懸濁液とした。
ヘリコバクター・ピロリ抗原特異的Th1反応に対する乳酸菌による抑制試験の結果を図3に示す。無刺激群ではIFN−γの産生が認められないのに対し、無刺激群にヘリコバクター・ピロリ加熱菌体を添加した対照群では、ヘリコバクター・ピロリ抗原特異的反応によるIFN−γの産生が認められた。乳酸菌加熱菌体として、ラクトバチルス・ガセリOLL 2716株(FERM BP−6999)加熱菌体を添加した比較群のIFN−γ産生量は、対照群に対して有意な差は認められなかった。
Claims (12)
- ラクトバチルス・ガセリ(Lactobacillus gasseri)MCC1183株(受託番号:FERM P−21908)。
- ラクトバチルス・ガセリMCC1183株を含有する医薬。
- ラクトバチルス・ガセリMCC1183株を含有する飲食品。
- ラクトバチルス・ガセリMCC1183株を含有する飼料。
- ラクトバチルス・ガセリMCC1183株を含有する抗菌剤。
- ヘリコバクター・ピロリ(Helicobacter pylori)の抗菌に用いられる、請求項5に記載の抗菌剤。
- ラクトバチルス・ガセリMCC1183株を含有する抗炎症剤。
- ヘリコバクター・ピロリに起因する胃炎の予防又は治療に用いられる、請求項7に記載の抗炎症剤。
- ラクトバチルス・ガセリMCC1183株を含有する抗潰瘍剤。
- ヘリコバクター・ピロリに起因する胃潰瘍又は十二指腸潰瘍の予防又は治療に用いられる、請求項9に記載の抗潰瘍剤。
- ラクトバチルス・ガセリMCC1183株を含有する免疫抑制剤。
- ヘリコバクター・ピロリによって誘発されるTh1細胞の免疫反応を抑制するために用いられる、請求項11に記載の免疫抑制剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010073674A JP5300772B2 (ja) | 2010-03-26 | 2010-03-26 | 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010073674A JP5300772B2 (ja) | 2010-03-26 | 2010-03-26 | 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011200211A JP2011200211A (ja) | 2011-10-13 |
JP5300772B2 true JP5300772B2 (ja) | 2013-09-25 |
Family
ID=44877682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010073674A Expired - Fee Related JP5300772B2 (ja) | 2010-03-26 | 2010-03-26 | 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5300772B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017221799A1 (ja) * | 2016-06-20 | 2017-12-28 | 株式会社明治 | 上部消化管内菌叢改善剤 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150283187A1 (en) | 2012-11-16 | 2015-10-08 | Calpis Co., Ltd. | Agent for alleviating stress-induced bowel disorder containing specific lactobacillus gasseri strain or treated product thereof |
JP5965368B2 (ja) * | 2013-08-30 | 2016-08-03 | 森永乳業株式会社 | D−アミノ酸の製造方法 |
CN106029081A (zh) * | 2014-02-28 | 2016-10-12 | 株式会社明治 | 功能性消化道障碍预防和/或改善剂 |
WO2018084172A1 (ja) * | 2016-11-01 | 2018-05-11 | 学校法人慶応義塾 | Th1細胞を誘導する細菌 |
WO2019017389A1 (ja) * | 2017-07-18 | 2019-01-24 | 学校法人慶應義塾 | Th1細胞誘導性細菌に対する抗菌組成物 |
AU2019274351B2 (en) | 2018-05-23 | 2022-04-07 | Kobiolabs, Inc. | Lactobacillus gasseri KBL697 strain and use thereof |
WO2020179868A1 (ja) | 2019-03-07 | 2020-09-10 | 学校法人慶應義塾 | 薬剤耐性細菌又は炎症惹起性細菌に対する抗菌組成物 |
DE102019007892A1 (de) * | 2019-11-14 | 2021-05-20 | Belano Medical Ag | Neue Formulierung von Lactobacillus-Stämmen zur Therapie und Prophylaxe der Besiedlung mit Helicobacter pylori in den oberen Atemwegen und Verdauungssystem |
KR102537844B1 (ko) * | 2020-12-28 | 2023-05-30 | 건국대학교 글로컬산학협력단 | 마리골드 추출물에 모유 유산균으로 생물전환 시킨 성분을 함유하는 항균, 항산화 및 항염증 활성을 갖는 조성물 |
CN114561313B (zh) * | 2021-08-26 | 2022-09-13 | 佛山市孛特碧欧微生物科技有限公司 | 格氏乳杆菌及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100357668B1 (ko) * | 2000-02-19 | 2002-10-18 | 주식회사 한국야쿠르트 | 헬리코박터 필로리에 대해 항균활성을 갖는 락토바실러스애시도필러스 에이치 와이 2177, 락토바실러스 카제이에이치 와이2743 및 그를 이용한 유산균 제제, 발효유 |
SE0103695D0 (sv) * | 2001-11-07 | 2001-11-07 | Thomas Boren | A novel non-antibiotic strategy against OGIP infections based on a cereal product |
US20040208863A1 (en) * | 2003-01-30 | 2004-10-21 | James Versalovic | Anti-inflammatory activity from lactic acid bacteria |
-
2010
- 2010-03-26 JP JP2010073674A patent/JP5300772B2/ja not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017221799A1 (ja) * | 2016-06-20 | 2017-12-28 | 株式会社明治 | 上部消化管内菌叢改善剤 |
JPWO2017221799A1 (ja) * | 2016-06-20 | 2019-04-11 | 株式会社明治 | 上部消化管内菌叢改善剤 |
JP7101354B2 (ja) | 2016-06-20 | 2022-07-15 | 株式会社明治 | 上部消化管内菌叢改善剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2011200211A (ja) | 2011-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5300772B2 (ja) | 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料 | |
US11566219B2 (en) | Bifidobacterium bacteria and composition including novel bifidobacterium bacteria | |
US10653730B2 (en) | Lactic acid bacterium, drug, food or drink, and feed which contain the lactic acid bacterium | |
JP5261617B2 (ja) | 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料 | |
EP3725321A1 (en) | Composition containing bacterium belonging to genus bifidobacterium as active ingredient | |
WO2007020884A1 (ja) | β-ディフェンシンを介した感染予防効果を有するビフィズス菌または乳酸菌とそれを含有する食品・医薬品組成物 | |
JP5784327B2 (ja) | 抗菌剤 | |
US11241463B2 (en) | Lactic acid bacterium, drug, food or drink, and feed which contain the lactic acid bacterium | |
JP7240327B2 (ja) | 新規ビフィドバクテリウム属細菌及び当該細菌を含む組成物 | |
JP6998193B2 (ja) | 新規ビフィドバクテリウム属細菌及び当該細菌を含む組成物 | |
JP2012180288A (ja) | 抗菌剤 | |
WO2020251044A1 (ja) | ビフィドバクテリウム属細菌を有効成分とする組成物 | |
KR20210046498A (ko) | 비피도박테리움 비피덤을 포함하는 면역력 증강 또는 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111212 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130521 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130618 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5300772 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |